REGENXBIO (NASDAQ:RGNX) Stock Price Down 6.1% – Should You Sell?

REGENXBIO Inc. (NASDAQ:RGNX) shares traded down 6.1% on Friday . The company traded as low as $10.62 and last traded at $10.5940. 194,626 shares were traded during mid-day trading, a decline of 87% from the average session volume of 1,452,026 shares. The stock had previously closed at $11.28.

Key Stories Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Q2 results exceeded expectations. REGENXBIO reported adjusted earnings of $0.43 per share, well above analyst estimates ranging from $0.08 to $0.12, while revenue of $108.02 million surpassed the $97.63 million consensus estimate. The result compared with a $1.38-per-share loss in the year-ago quarter. REGENXBIO Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Cash runway and regulatory milestones improved visibility. The company said more than $200 million of new capital raised in July extended its cash runway into the fourth quarter of 2027. The RGX-202 biologics license application for Duchenne muscular dystrophy remains on track to begin in the third quarter of 2026, with potential accelerated approval in the second half of 2027. REGENXBIO Q2 2026 Financial Results
• Positive Sentiment: Multiple clinical catalysts remain ahead. Topline data from the ATMOSPHERE and ASCENT studies of ABBV-RGX-314 for wet age-related macular degeneration are expected in the fourth quarter of 2026. REGENXBIO also reaffirmed a third-quarter 2026 resubmission plan for RGX-121 in Hunter syndrome following an FDA Type A meeting. REGENXBIO Cash Runway and RGX-202 Update
• Neutral Sentiment: Barclays maintained an “Equal Weight” rating but raised or reaffirmed a $12 price target, implying roughly 15% upside from the cited share price. The target suggests measured optimism rather than a strongly bullish view. Barclays Rating Update
• Negative Sentiment: REGENXBIO remains financially loss-making. Despite the quarterly profit, the company reported a deeply negative net margin, and analysts still expect a full-year loss. The stock therefore remains highly dependent on successful clinical results, regulatory filings and future commercialization.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on RGNX shares. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of REGENXBIO in a research note on Wednesday, July 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of REGENXBIO in a research note on Monday, June 8th. Leerink Partners raised their target price on REGENXBIO from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Zacks Research cut REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Finally, Barclays downgraded REGENXBIO from an “overweight” rating to a “positive” rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $23.82.

REGENXBIO Price Performance

The stock has a fifty day moving average price of $9.94 and a 200 day moving average price of $9.42. The stock has a market capitalization of $535.61 million, a P/E ratio of -1.86 and a beta of 0.94.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.35. REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The company had revenue of $108.02 million during the quarter, compared to analysts’ expectations of $97.63 million. Research analysts anticipate that REGENXBIO Inc. will post -3.69 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Steve Pakola sold 36,725 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50. Following the sale, the insider directly owned 213,009 shares in the company, valued at $2,739,295.74. This represents a 14.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 73,803 shares of company stock worth $886,937. 14.22% of the stock is owned by insiders.

Hedge Funds Weigh In On REGENXBIO

A number of large investors have recently modified their holdings of RGNX. AQR Capital Management LLC increased its holdings in REGENXBIO by 2,247.7% during the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after acquiring an additional 594,161 shares during the period. Jane Street Group LLC boosted its holdings in REGENXBIO by 151.1% in the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock valued at $2,961,000 after purchasing an additional 249,156 shares during the period. Franklin Resources Inc. purchased a new position in shares of REGENXBIO during the 2nd quarter valued at $239,000. American Century Companies Inc. grew its position in shares of REGENXBIO by 8.4% during the 2nd quarter. American Century Companies Inc. now owns 110,066 shares of the biotechnology company’s stock valued at $904,000 after purchasing an additional 8,487 shares in the last quarter. Finally, Prudential Financial Inc. bought a new position in shares of REGENXBIO in the second quarter worth $87,000. 88.08% of the stock is currently owned by institutional investors.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.